DexCom, Inc. $DXCM Shares Acquired by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 207.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 13,199 shares of the medical device company’s stock after purchasing an additional 8,905 shares during the period. Azzad Asset Management Inc. ADV’s holdings in DexCom were worth $888,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Andra AP fonden purchased a new position in shares of DexCom in the 2nd quarter valued at about $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in DexCom in the second quarter valued at approximately $26,000. SJS Investment Consulting Inc. lifted its stake in DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after acquiring an additional 384 shares during the last quarter. Financial Consulate Inc. acquired a new position in DexCom during the 3rd quarter worth approximately $29,000. Finally, Sound Income Strategies LLC increased its position in shares of DexCom by 83.8% in the 3rd quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 285 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

DXCM has been the subject of several recent analyst reports. Canaccord Genuity Group set a $99.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, February 4th. Argus lowered their price objective on DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Robert W. Baird set a $82.00 target price on DexCom in a research report on Friday, October 31st. Finally, Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.00.

Insider Activity at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the sale, the director owned 27,031 shares in the company, valued at $1,569,690.17. This represents a 3.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard Alexander Collins sold 2,906 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the transaction, the director directly owned 35,088 shares in the company, valued at $2,071,946.40. The trade was a 7.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.32% of the stock is currently owned by corporate insiders.

DexCom Stock Up 0.3%

Shares of NASDAQ DXCM opened at $70.16 on Tuesday. The business has a 50-day moving average price of $68.80 and a 200 day moving average price of $70.07. The stock has a market cap of $27.36 billion, a PE ratio of 38.98, a price-to-earnings-growth ratio of 1.25 and a beta of 1.49. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.